Intellia Therapeutics Files 2024 10-K
Ticker: NTLA · Form: 10-K · Filed: Feb 27, 2025 · CIK: 1652130
Sentiment: neutral
Topics: 10-K, biotechnology, clinical-stage, financials
Related Tickers: REGN
TL;DR
Intellia dropped its 2024 10-K. All the deets on cash, pipeline, and risks for NTLA.
AI Summary
Intellia Therapeutics, Inc. filed its 2024 10-K on February 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on in vitro and in vivo diagnostic substances, is based in Cambridge, MA. Key financial details and operational highlights from the past fiscal year are detailed within this comprehensive filing.
Why It Matters
This filing provides investors and stakeholders with a detailed overview of Intellia Therapeutics' financial performance, strategic initiatives, and risk factors for the fiscal year 2024, crucial for understanding the company's current standing and future outlook.
Risk Assessment
Risk Level: medium — As a clinical-stage biotechnology company, Intellia Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2835 — SIC Code (Industry classification for In Vitro & In Vivo Diagnostic Substances)
- 001-37766 — SEC File Number (Company's SEC filing identifier)
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-02-27 (date) — Filing date
- Cambridge, MA (location) — Company headquarters
- Regeneron Pharmaceuticals, Inc. (company) — Mentioned in relation to agreements
FAQ
What was Intellia Therapeutics' primary business activity as indicated by its SIC code?
Intellia Therapeutics' primary business activity is in 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES', as indicated by its SIC code 2835.
On what date was the 10-K filing for the fiscal year ending December 31, 2024, submitted?
The 10-K filing for the fiscal year ending December 31, 2024, was filed on February 27, 2025.
Where is Intellia Therapeutics, Inc. headquartered?
Intellia Therapeutics, Inc. is headquartered at 40 Erie Street, Suite 130, Cambridge, MA 02139.
What is the SEC file number for Intellia Therapeutics, Inc.?
The SEC file number for Intellia Therapeutics, Inc. is 001-37766.
Does the filing mention any specific agreements or collaborations with other companies?
Yes, the filing mentions 'Regeneron Pharmaceuticals, Inc.' in relation to the 'TwoThousandSixteenRegeneronAgreementMember'.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 27, 2025 regarding Intellia Therapeutics, Inc. (NTLA).